18.04.2024 14:45:07 - dpa-AFX: GNW-Adhoc: Renovaro Inc. Proudly Announces the Appointment Of Professor Dr. Geert Kazemier as the Chairman of its Scientific Advisory Board, A Move That Heralds a New Era of Innovation and Progress in its Mission to Reshape Cancer Screening, Diag
LOS ANGELES and AMSTERDAM, April 18, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc.
(Nasdaq: RENB), a pioneer in cancer diagnostics and therapeutics powered by
artificial intelligence, announces the distinguished Professor Geert Kazemier,
MD, PhD, as the new Chairman of its Scientific Advisory Board. This pivotal move
signifies a major leap forward in Renovaro's quest to redefine cancer diagnosis
and treatment through cutting-edge AI and immunotherapy technologies.
Professor Kazemier is the Clinical Director and scientific co-director of the
Cancer Center at Amsterdam University Medical Center. The center has an
extensive repository of biobank tumor material and liquid biopsies, including an
extensive range of data from biomarkers, amongst others, for co-rectal,
urogenital, lung, and breast cancers.
Professor Kazemier has made groundbreaking contributions to oncology and
surgical research. His depth of experience and trailblazing academic and
clinical leadership align perfectly with Renovaro's mission. Professor
Kazemier's commitment to medical advancement positions him as an ideal leader to
propel Renovaro's Scientific Advisory Board during a transformative era in
oncology characterized by the integration of Artificial Intelligence.
Under Professor Kazemier's direction, Amsterdam University Medical Center's
Cancer Center has launched numerous pioneering research projects, substantially
enriching our understanding and treatment of cancer. His drive for innovation
and excellence echoes Renovaro's dedication to advancing early diagnosis,
accurate response prediction, effective monitoring, and personalized therapy.
As the Chairman of the Scientific Advisory Board, Professor Kazemier is set to
influence Renovaro's research and development trajectory. We believe his
expertise and forward-thinking approach will guide Renovaro in refining the
company's strategic initiatives, including data acquisition and biomarker
selection, to position Renovaro at the forefront of innovation. His leadership
will prioritize novel research paths with the power to potentially transform
cancer diagnosis, monitoring, and treatment processes.
"We are honored to have Professor Kazemier join our team," remarked Hon Mark
Dybul, MD, CEO of Renovaro. "His extraordinary achievements in medical research
and visionary leadership are tremendous assets to Renovaro. With Professor
Kazemier guiding our Scientific Advisory Board, we are even more confident in
our global mission to revolutionize patient care through regenerative medicine."
Expressing his excitement, Professor Kazemier shared, "I am enthusiastic about
playing a role in the evolution of Renovaro's AI platform, 'the Cube,' having
witnessed its growth from inception to its current state. I am excited to
further contribute to Renovaro's groundbreaking efforts to reshape the landscape
of cancer care. I believe the Cube's potential to shift cancer patient care from
diagnosis to therapy is extraordinary. I eagerly anticipate collaborating with
Renovaro's gifted team to steer the company's research towards transformative
medical innovations."
With Professor Kazemier's appointment, Renovaro cements its status as an
AI/biotech frontrunner, ready to drive significant advancements in medical
science and enhance patient outcomes in the fight against cancer.
About Renovaro:
Renovaro aims to accelerate precision and personalized medicine for longevity
powered by mutually reinforcing AI and biotechnology platforms for early
diagnosis, better-targeted treatments, and drug discovery. Renovaro includes
Renovaro Biosciences with its advanced cell-gene immunotherapy company and
Renovaro Cube. Renovaro Cube has developed an award-winning AI platform that is
committed to the early detection of cancer and its recurrence and monitoring
subsequent treatments. Renovaro Cube intervenes at a stage where potential
therapy can be most effective. Renovaro Cube is a molecular data science company
with a background in FinTech and a 10-year history. It brings together
proprietary artificial intelligence (AI) technology, multi-omics, multi-modal
data, and the expertise of a carefully selected multidisciplinary team to
radically accelerate precision medicine and enable breakthrough changes in
cancer care.
Upon the closing of the previously announced acquisition of Cyclomics (winner of
the Health Holland Venture Challenge), Renovaro Cube will be capable of
performing liquid biopsies using proprietary technologies to identify single
cancer DNA molecules in only one vial of blood. In combination with Oxford
Nanopore Technology, genetic information can be retrieved over multiple genetic
layers to develop the next generation of cancer diagnostics. This will transform
cancer care by enabling faster and more accurate diagnosis throughout the
patient journey.
About Prof. Kazemier
Professor Geert Kazemier, MD, PhD, went to medical school and trained as an
oncologic and transplant surgeon at Erasmus University Rotterdam, The
Netherlands. After a fellowship in hepatobiliary surgery and transplantation at
Universitätsklinikum-Eppendorf in Hamburg, Germany, he became a Consultant
Hepatobiliary Surgery and Transplantation at Erasmus Medical Center and was
later appointed Program Leader of Liver Transplantation there. In 2012, he was
appointed as a full hepatobiliary surgery and transplantation professor at
Amsterdam University Medical Center. He is currently the Clinical Director and
Scientific co-director of Cancer Center Amsterdam at Amsterdam UMC. In his
research, he aims to put fundamental research to work in clinical practice as he
focuses on developing biomarkers for pancreatic and bile duct cancer and
investigating the added value of Artificial Intelligence in liver tumors.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are
forward-looking statements. These statements are only predictions based on
current information and expectations and involve a number of risks and
uncertainties, including but not limited to the success or efficacy of our
pipeline and platform. All statements other than historical facts are forward-
looking statements, which can be identified by the use of forward-looking
terminology such as "believes," "plans," "expects," "aims," "intends,"
"potential," or similar expressions. Actual events or results may differ
materially from those projected in any of such statements due to various
uncertainties, including as set forth in Renovaro's most recent Annual Report on
Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the date hereof. All
forward-looking statements are qualified in their entirety by this cautionary
statement, and Renovaro Inc. undertakes no obligation to revise or update this
press release to reflect events or circumstances after the date hereof.
For media inquiries, please contact: karen@renovarocube.com
(mailto:karen@renovarocube.com)
Source: Renovaro Inc.
Â